Literature DB >> 22496950

Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome.

Michael S Kostapano, Niki Katsiki, Vasilios G Athyros, Asterios Karagiannis, Dimitri P Mikhailidis.   

Abstract

Entities:  

Year:  2012        PMID： 22496950      PMCID： PMC3321328          DOI： 10.5001/omj.2012.39

Source DB:  PubMed          Journal:  Oman Med J        ISSN： 1999-768X


× No keyword cloud information.
  11 in total

Review 1.  Liver enzymes: potential cardiovascular risk markers?

Authors:  Eirini Lioudaki; Emmanuel S Ganotakis; Dimitri P Mikhailidis
Journal:  Curr Pharm Des       Date:  2011-11       Impact factor: 3.116

Review 2.  Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?

Authors:  Sofia G Tsouli; Evangelos N Liberopoulos; Dimitri P Mikhailidis; Vasilios G Athyros; Moses S Elisaf
Journal:  Metabolism       Date:  2006-10       Impact factor: 8.694

Review 3.  Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia.

Authors:  S S Daskalopoulou; V Tzovaras; D P Mikhailidis; M Elisaf
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

4.  Uric acid: a cardiovascular risk factor in patients with recent myocardial infarction.

Authors:  Giacomo Levantesi; Rosa Maria Marfisi; Maria Grazia Franzosi; Aldo Pietro Maggioni; Gian Luigi Nicolosi; Carlo Schweiger; Maria Giuseppina Silletta; Luigi Tavazzi; Gianni Tognoni; Roberto Marchioli
Journal:  Int J Cardiol       Date:  2012-01-20       Impact factor: 4.164

5.  Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study.

Authors:  Vasilios G Athyros; Dimitri P Mikhailidis; Evangelos N Liberopoulos; Anna I Kakafika; Asterios Karagiannis; Athanasios A Papageorgiou; Konstantinos Tziomalos; Emmanuel S Ganotakis; Moses Elisaf
Journal:  Nephrol Dial Transplant       Date:  2006-09-23       Impact factor: 5.992

6.  Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.

Authors:  Vasilios G Athyros; Konstantinos Tziomalos; Thomas D Gossios; Theodora Griva; Panagiotis Anagnostis; Konstantinos Kargiotis; Efstathios D Pagourelias; Eleni Theocharidou; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Lancet       Date:  2010-11-23       Impact factor: 79.321

Review 7.  Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?

Authors:  Niki Katsiki; Vasilios G Athyros; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Curr Vasc Pharmacol       Date:  2011-11       Impact factor: 2.719

8.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

9.  Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome.

Authors:  Zeina A Al-Thanoon; Isam H Mahmood
Journal:  Oman Med J       Date:  2012-01

10.  Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.

Authors:  Michael Hecht Olsen; Kristian Wachtell; Gareth Beevers; Björn Dahlöf; Giovanni de Simone; Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Lars H Lindholm; Paulette A Lyle; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  J Hypertens       Date:  2009-03       Impact factor: 4.844
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.